The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency

29Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Factor V deficiency is a rare hereditary bleeding disorder. Currently, FV concentrates are not available, and the treatment of spontaneous bleeding or bleeding associated with invasive procedures is transfusion of fresh frozen plasma (FFP). However, FFP transfusion can lead to the development of inhibitor to FV, and is associated with several potential transfusion reactions including allergic reactions. We report a patient with congenital severe FV deficiency with repeated haemarthroses of a shoulder joint, and progressively severe allergic reactions to FFP transfusions. In addition, the patient also developed acute pulmonary oedema. Activated recombinant coagulation factor VII (rFVIIa) was used as an alternative haemostatic agent to FFP. We describe the use of rFVIIa in this patient during haemarthroses, synovectomy, and physiotherapy. © 2005 Blackwell Publishing Ltd.

Cite

CITATION STYLE

APA

González-Boullosa, R., Ocampo-Martínez, R., Alarcón-Martín, M. J., Suárez-Rodríguez, M., Domínguez-Viguera, L., & González-Fajo, G. (2005). The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency. Haemophilia, 11(2), 167–170. https://doi.org/10.1111/j.1365-2516.2005.00956.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free